- Biomerieux
- Danaher Corp.
- Becton, Dickinson and Co.
- Abbott
- Roche Diagnostics
- Bruker, Hologic
- Bio-Rad
- Qiagen
- Thermo Fisher Scientific
- Agilent
- Merck KGaA
- Shimadzu
- 3M
- Neogen
(Note: The list of major players will be updated with the latest market scenario and trends)
Recent developments by key players in the clinical microbiology market:
Biomerieux
- March 2023: Launched the VITEK?MS PRIME, a next-generation MALDI-TOF mass spectrometry system for microbial identification, offering faster time-to-result and an expanded pathogen database to enhance lab efficiency
- Partnered with Specific Diagnostics in January 2023, acquiring technology to speed up antimicrobial susceptibility testing (AST) — bolstering bioMérieux’s ability to tackle AMR
- Introduced newer capabilities in syndromic testing through expanded BioFire panels, covering respiratory and gastrointestinal pathogens in multiplex PCR assays
Roche Diagnostics
- January 2022: Rolled out the compact cobas® 5800 System—a modular molecular diagnostics platform that enables pathogen detection for smaller and medium-sized labs.
- Advanced development of antibiotics targeting carbapenem-resistant Gram-negative bacteria, partnering with BARDA to address high-priority AMR pathogens
Thermo Fisher Scientific
- September 2023: Acquired Olink, enhancing its portfolio in protein biomarker diagnostics, complementing its clinical microbiology and molecular testing capabilities.
- Introduced the QuantStudio 7 Pro Dx Real-Time PCR System, designed to increase sensitivity and flexibility in pathogen detection across high-demand settings.
Becton, Dickinson and Co.
- Into 2023: BD’s Phoenix and BACTEC systems continue to evolve with full automation for AST and culture systems supporting faster diagnostics in infectious disease workflows.
- Cepheid’s Xpert Xpress portfolio expanded with the MVP multiplex PCR test for BV, Candida, and Trichomonas from a single sample.
Bruker, Hologic
- Bruker launched the MALDI Biotyper® Sirius system in April 2021, offering an enhanced microbial identification library and accelerated results
- QIAGEN’s QIAstat-Dx Rise syndromic testing platform allows simultaneous detection of multiple pathogens—with relevance for GI and respiratory panels.
In April 2022, DCN Dx, a US-based company that specialises in the creation of rapid diagnostic tests, purchased Biomed Diagnostics Inc. for an undisclosed amount. Through this acquisition, DCN Diagnostics aims to increase both its clinical microbiology product range and its market share in microbial testing.
In July 2021, Bruker unveiled brand-new microbiology workflows and tools for microbial identification and infection control. It includes products like the MBT Lipid Xtract kit that expand the area of research beyond rapid microbial identification.
One of the main factors driving the market's growth is the rising prevalence of infectious diseases in the world. Additionally, as air and water pollution levels rise, more people are developing respiratory illnesses, which in turn is fueling the market. In addition, the inclusion of automation in clinical microbiology is enhancing the efficiency of laboratory operations, enabling specimen traceability, and eradicating incubation delays. All of these factors are favourable for market growth. The top players are also putting a great deal of effort into developing technology breakthroughs in disease diagnostics, like the use of machine learning (ML), which helps with producing precise and quick results. Clinical microbiology combined with the emergence of many molecular diagnostic methods, is providing the industry with abundant growth prospects. However, the government's rigorous regulations, lack of qualified workers, and the delay in the authorization of microbiology diagnostic tests are among the diverse regulatory frameworks that are projected to have a detrimental impact on market growth to a certain extent.
FutureWise Market Research has published a report that provides an insightful analysis of Clinical Microbiology Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts projects that Clinical Microbiology Market will experience a significant growth. According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.